METABIOTICS AS A NEW MEANS OF REDUCING THE LEVEL OF HOMOCYSTEINE IN THE BLOOD OF PATIENTS WITH LATE STAGES OF PARKINSON'S DISEASE
Patients with late stages of Parkinson`s disease often have hyperhomocisteinemia, which is a risk factor of arterial and venous thrombosis. To reduce the level of homocysteine in the blood, we examined 20 patients and 10 people in the control group, who were measured the level of homocysteine in the blood before and after the course of taking metabiotics. The purpose of the study was to prove: the level of homocysteine in the blood depends on the state of intestinal microflora; taking BAA "Actoflor-C" can reduce the level of homocysteine in the blood. There was a decrease in the level of homocysteine in the blood after taking the metabiotic by 13.4% on average (13.33± QUOTE 2.57 µmol/l to 11.49± QUOTE 2.53 µmol/l after, p<0.05). This study showed: when the titer of bifidobacterias increases, the level of homocysteine in the blood decreases; using of metabiotics, a complex of analogues of probiotic bacteria metabolites, which increases physiological activity and stimulates the growth of human beneficial microflora, helps to reduce the level of homocysteine in the blood of patients with Parkinson's disease in the later stages.